Back to Trials
NCT04216732Recruiting

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

M.D. Anderson Cancer Center

Start Date

1/10/2020

Completion Date

9/1/2026

Summary

This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.

Detailed Description

PRIMARY OBJECTIVES: I. To describe the natural history of medullary thyroid cancer (MTC) using a comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in our existing multi-institutional patient registry. Ia. To describe the demographic, clinical, pathologic, and genotypic variables associated with each phase of disease. Ib. To identify those variables which are predictors of progression to the most advanced phases of disease that require small molecule therapy, including commercially approved and experimental agents. II. To characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs). IIa. To describe clinical, psychosocial, economic, and physical well-being variables and the subsequent impact on quality of life associated with each phase of disease. IIb. To evaluate longitudinal changes in clinical, psychosocial, economic, and physical well-being variables between and within all phases of MTC, and the subsequent impact they have on quality of life. III. To evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial. OUTLINE: AIM I \& II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease. AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks. The questionnaire data gets paired with the collected medical record history that is maintained in the Registry.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Aims 1 and 2: A diagnosis of MTC * Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment * Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team * Aim 3: A current registrant in the MTCR

Interventions

OTHER

Blood Pressure Measurement

OTHER

Questionnaire Administration

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Advanced Thyroid Gland Medullary CarcinomaStage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8

Locations

University of California San Francisco

San Francisco, California 94143

United States

M D Anderson Cancer Center

Houston, Texas 77030

United States